<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease - Cooper, TE - 2023 | Cochrane Library</title> <meta content="Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease - Cooper, TE - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007751.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease - Cooper, TE - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007751.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007751.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease" name="citation_title"/> <meta content="Tess E Cooper" name="citation_author"/> <meta content="The University of Sydney" name="citation_author_institution"/> <meta content="Claris Teng" name="citation_author"/> <meta content="The Children's Hospital at Westmead" name="citation_author_institution"/> <meta content="David J Tunnicliffe" name="citation_author"/> <meta content="The University of Sydney" name="citation_author_institution"/> <meta content="david.tunnicliffe@sydney.edu.au" name="citation_author_email"/> <meta content="Brydee A Cashmore" name="citation_author"/> <meta content="The University of Sydney and The Children's Hospital at Westmead" name="citation_author_institution"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD007751.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/07/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007751.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007751.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007751.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Angiotensin Receptor Antagonists [adverse effects]; Angiotensin-Converting Enzyme Inhibitors [adverse effects]; *Diabetes Mellitus [drug therapy]; Losartan [therapeutic use]; Proteinuria; *Renal Insufficiency, Chronic [complications, drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007751.pub3&amp;doi=10.1002/14651858.CD007751.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZCrlluee";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007751\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007751\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ko","ms","hr","fa","id","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007751.pub3",title:"Angiotensin\\u2010converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non\\u2010diabetic chronic kidney disease",firstPublishedDate:"Jul 19, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007751.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007751.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007751.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007751.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007751.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007751.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007751.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007751.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007751.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007751.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2816 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007751.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-sec-0107"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-sec-0101"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/appendices#CD007751-sec-0112"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/supinfo/CD007751-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/supinfo/CD007751-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information#CD007751-cr-0004">Tess E Cooper</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information#CD007751-cr-0005">Claris Teng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information#CD007751-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>David J Tunnicliffe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information#CD007751-cr-0007">Brydee A Cashmore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information#CD007751-cr-0008">Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information/en#CD007751-sec-0120">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 July 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007751.pub3">https://doi.org/10.1002/14651858.CD007751.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007751-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007751-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007751-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007751-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007751-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007751-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007751-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007751-abs-0001" lang="en"> <section id="CD007751-sec-0001"> <h3 class="title" id="CD007751-sec-0001">Background</h3> <p>Chronic kidney disease (CKD) is a long‐term condition that occurs as a result of damage to the kidneys. Early recognition of CKD is becoming increasingly common due to widespread laboratory estimated glomerular filtration rate (eGFR) reporting, raised clinical awareness, and international adoption of the Kidney Disease Improving Global Outcomes (KDIGO) classifications. Early recognition and management of CKD affords the opportunity to prepare for progressive kidney impairment and impending kidney replacement therapy and for intervention to reduce the risk of progression and cardiovascular disease. Angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are two classes of antihypertensive drugs that act on the renin‐angiotensin‐aldosterone system. Beneficial effects of ACEi and ARB on kidney outcomes and survival in people with a wide range of severity of kidney impairment have been reported; however, their effectiveness in the subgroup of people with early CKD (stage 1 to 3) is less certain. </p> <p>This is an update of a review that was last published in 2011.</p> </section> <section id="CD007751-sec-0002"> <h3 class="title" id="CD007751-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of ACEi and ARB or both in the management of people with early (stage 1 to 3) CKD who do not have diabetes mellitus (DM). </p> </section> <section id="CD007751-sec-0003"> <h3 class="title" id="CD007751-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 6 July 2023 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and Embase, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal, and ClinicalTrials.gov. </p> </section> <section id="CD007751-sec-0004"> <h3 class="title" id="CD007751-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) reporting the effect of ACEi or ARB in people with early (stage 1 to 3) CKD who did not have DM were selected for inclusion. Only studies of at least four weeks duration were selected. Authors independently assessed the retrieved titles and abstracts and, where necessary, the full text to determine which satisfied the inclusion criteria. </p> </section> <section id="CD007751-sec-0005"> <h3 class="title" id="CD007751-sec-0005">Data collection and analysis</h3> <p>Data extraction was carried out by two authors independently, using a standard data extraction form. The methodological quality of included studies was assessed using the Cochrane risk of bias tool. Data entry was carried out by one author and cross‐checked by another. When more than one study reported similar outcomes, data were pooled using the random‐effects model. Heterogeneity was analysed using a Chi² test and the I² test. Results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes and mean difference (MD) and 95% CI for continuous outcomes. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach </p> </section> <section id="CD007751-sec-0006"> <h3 class="title" id="CD007751-sec-0006">Main results</h3> <p>Six studies randomising 9379 participants with CKD stages 1 to 3 (without DM) met our inclusion criteria. Participants were adults with hypertension; 79% were male from China, Europe, Japan, and the USA. Treatment periods ranged from 12 weeks to three years. Overall, studies were judged to be at unclear or high risk of bias across all domains, and the quality of the evidence was poor, with GRADE rated as low or very low certainty. </p> <p>In low certainty evidence, ACEi (benazepril 10 mg or trandolapril 2 mg) compared to placebo may make little or no difference to death (any cause) (2 studies, 8873 participants): RR 2.00, 95% CI 0.26 to 15.37; I² = 76%), total cardiovascular events (2 studies, 8873 participants): RR 0.97, 95% CI 0.90 to 1.05; I² = 0%), cardiovascular‐related death (2 studies, 8873 participants): RR 1.73, 95% CI 0.26 to 11.66; I² = 54%), stroke (2 studies, 8873 participants): RR 0.76, 95% CI 0.56 to 1.03; I² = 0%), myocardial infarction (2 studies, 8873 participants): RR 1.00, 95% CI 0.84 to 1.20; I² = 0%), and adverse events (2 studies, 8873 participants): RR 1.33, 95% CI 1.26 to 1.41; I² = 0%). </p> <p>It is uncertain whether ACEi (benazepril 10 mg or trandolapril 2 mg) compared to placebo reduces congestive heart failure (1 study, 8290 participants): RR 0.75, 95% CI 0.59 to 0.95) or transient ischaemic attack (1 study, 583 participants): RR 0.94, 95% CI 0.06 to 15.01; I² = 0%) because the certainty of the evidence is very low. </p> <p>It is uncertain whether ARB (losartan 50 mg) compared to placebo (1 study, 226 participants) reduces: death (any‐cause) (no events), adverse events (RR 19.34, 95% CI 1.14 to 328.30), eGFR rate of decline (MD 5.00 mL/min/1.73 m<sup>2</sup>, 95% CI 3.03 to 6.97), presence of proteinuria (MD ‐0.65 g/24 hours, 95% CI ‐0.78 to ‐0.52), systolic blood pressure (MD ‐0.80 mm Hg, 95% CI ‐3.89 to 2.29), or diastolic blood pressure (MD ‐1.10 mm Hg, 95% CI ‐3.29 to 1.09) because the certainty of the evidence is very low. </p> <p>It is uncertain whether ACEi (enalapril 20 mg, perindopril 2 mg or trandolapril 1 mg) compared to ARB (olmesartan 20 mg, losartan 25 mg or candesartan 4 mg) (1 study, 26 participants) reduces: proteinuria (MD ‐0.40, 95% CI ‐0.60 to ‐0.20), systolic blood pressure (MD ‐3.00 mm Hg, 95% CI ‐6.08 to 0.08) or diastolic blood pressure (MD ‐1.00 mm Hg, 95% CI ‐3.31 to 1.31) because the certainty of the evidence is very low. </p> </section> <section id="CD007751-sec-0007"> <h3 class="title" id="CD007751-sec-0007">Authors' conclusions</h3> <p>There is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have DM. The available evidence is overall of very low certainty and high risk of bias. We have identified an area of large uncertainty for a group of patients who account for most of those diagnosed as having CKD. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007751-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007751-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007751-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007751-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007751-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007751-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007751-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD007751-abs-0013">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007751-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007751-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007751-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007751-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007751-abs-0002" lang="en"> <h3>Blood pressure lowering medication for adults with early stages of chronic kidney disease (without diabetes) </h3> <p><b>What is the issue?</b> </p> <p>Chronic kidney disease (CKD) is a long‐term condition that occurs when the kidneys are damaged. It is important to diagnose and treat CKD in the early stages to prevent or delay the more serious stages of CKD (dialysis or transplant). People with CKD are at risk of cardiovascular disease (heart and lung disease). It is reported that blood pressure‐lowering medications can reduce or delay cardiovascular problems in adults with CKD (across early stages, dialysis, and transplant). However, we are less certain about these benefits in adults with early CKD (stages 1 to 3 only) who do not have diabetes. </p> <p>We wanted to discover whether taking blood pressure‐lowering medications is better or worse than placebo, and if so, which type of blood pressure‐lowering medication works best. </p> <p><b>What did we do?</b> </p> <p>We explored the evidence about the effect of blood pressure‐lowering medications on reducing patients' chance of death, cardiovascular disease and side effects or improving kidney function in people with early CKD (without diabetes). We found six poor‐quality studies. The evidence is current to 6 July 2023. </p> <p><b>What did we find?</b> </p> <p>We found six studies randomising a total of 9379 patients who have early CKD (stages 1 to 3 only, without diabetes). Patients were 18 to 75 years old, 79% were males, most had high blood pressure and were from China, Europe, Japan, and the USA. </p> <p>All six studies were considered to be at a high risk of bias. This was due to poorly described trial methods, not all of the patients were kept blind to their treatments, and there were high numbers of participants dropping out. Five out of the six studies were funded by the drug manufacturer or by an agency with a commercial interest in the results of the studies, one study did not declare their source of funding. </p> <p>1. Benazepril or trandolapril may reduce the chance of death, having a stroke, myocardial infarction, and side effects, but may or may not reduce the chance of congestive heart failure or transient ischaemic attack. </p> <p>2. Losartan may or may not reduce the chance of death, side effects or the presence of proteinuria and may not improve kidney function (eGFR) or blood pressure. </p> <p>3. Enalapril, perindopril, or trandolapril may or may not be any better than olmesartan, losartan, or candesartan for proteinuria and blood pressure. </p> <p><b>Conclusions</b> </p> <p>There is not enough evidence to know whether blood pressure‐lowering medications work well in patients with early CKD (stages 1 to 3) who do not have diabetes. We also do not know which type of blood pressure‐lowering medication is better than another. </p> <p>The quality and certainty of the evidence is considered to be very low. This is due to a high risk of bias in the studies, poorly conducted methods, and too little data from too few patients. We have identified an area of large uncertainty for further research. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007751-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007751-sec-0107"></div> <h3 class="title" id="CD007751-sec-0108">Implications for practice</h3> <section id="CD007751-sec-0108"> <p>With increased recognition of the importance and impact of CKD, the diagnosis and labelling of people with early (stage 1 to 3) CKD is now common. Drugs in the ACEi and ARB families are the cornerstone for the management of CKD. This review highlights that there have been very few studies that report on the effectiveness of ACEi and ARB drugs for patients with early CKD without those studies investigating single, specific kidney diagnoses. Despite the fact that people with early CKD are at greater risk of death (any cause) and cardiovascular events than progression to ESKD (<a href="./references#CD007751-bbs2-0092" title="DalyC . Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrology Dialysis Transplantation2007;22 Suppl 9:ix19-25. [MEDLINE: 17998227]">Daly 2007</a>; <a href="./references#CD007751-bbs2-0100" title="HallanSI , DahlK , OienCM , GrootendorstDC , AasbergA , HolmenJ , et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ2006;333(7577):1047. [MEDLINE: 17062598]">Hallan 2006</a>; <a href="./references#CD007751-bbs2-0123" title="SharmaP , McCulloughK , ScotlandG , McNameeP , PrescottG , MacLeodA , et al. Does stage-3 chronic kidney disease matter? A systematic literature review. British Journal of General Practice2010;60(575):e266-76. [EMBASE: 360210152]">Sharma 2010</a>), we found very few studies that considered the management of stage 1 to 3 CKD to reduce cardiovascular risk, death (any cause) or kidney disease progression. </p> <p>Our review demonstrated that there is currently insufficient evidence to determine the effectiveness of ACEi or ARB treatment for patients with stage 1 to 3 CKD who do not have DM. Studies have been conducted among patients with single, specific kidney diagnoses, but we have not included these here. Based on evidence from studies of specific kidney conditions, current clinical guidelines (<a href="./references#CD007751-bbs2-0112" title="LeveyAS , CoreshJ , BalkM , KauszAT , LevinA , SteffesMW , et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine2003;139(2):137-47. [MEDLINE: 12859163]">Levey 2003</a>; <a href="./references#CD007751-bbs2-0117" title="National Institute for Health and Clinical Excellence. Early identification and management of chronic kidney disease in adults in primary and secondary care. 2008. http://guidance.nice.org.uk/CG73 (accessed 17 January 2022).">NICE Guideline 2008</a>; <a href="./references#CD007751-bbs2-0124" title="Scottish Intercollegiate Guidelines Network. Diagnosis and management of chronic kidney disease. 2008. www.sign.ac.uk/guidelines/fulltext/103/index.html (last accessed August 2010).">SIGN Guideline 2008</a>) and practice supports the use of ACEi and ARB drugs for patients with proteinuric kidney disease. We have not found sufficient evidence to support any change in current practice. </p> </section> <h3 class="title" id="CD007751-sec-0109">Implications for research</h3> <section id="CD007751-sec-0109"> <p>Despite the growing international emphasis on the early detection and management of CKD and the recognition that stage 1 to 3 CKD accounts for most people with evidence of kidney impairment, we found very few studies that reported the effectiveness of ACEi or ARB in this population. </p> <p>We have identified an area of significant uncertainty for a group of patients who account for most of those labelled as having CKD. We identified more than 50 studies where relevant data may exist, but the subgroups of patients that are necessary to derive supported evidence were not presented in the original publications (see <a href="./references#CD007751-sec-0128" title="">Characteristics of excluded studies</a>). These studies may provide relevant subgroup or individual patient data for analysis of patients with stage 1 to 3 CKD. In addition, studies of ACEi (such as <a href="./references#CD007751-bbs2-0103" title="Heart Outcomes Prevention Evaluation Study Investigators, YusufS , SleightP , PogueJ , BoschJ , DaviesR , et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [Erratum in: 2000 May 4;342(18):1376] [Erratum in: N Engl J Med 2000 Mar 9;342(10):748]. New England Journal of Medicine2000;342(3):145-53. [MEDLINE: 10639539]">HOPE Study 1996</a>; PART 2 (<a href="./references#CD007751-bbs2-0115" title="MacMahonS , SharpeN , GambleG , ClagueA , MhurchuCN , ClarkT , et al. Randomized, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. Journal of the American College of Cardiology2000;36(2):438-43. [MEDLINE: 10933355]">MacMahon 2000</a>); <a href="./references#CD007751-bbs2-0118" title="PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358(9287):1033-41. [MEDLINE: 11589932]">PROGRESS Collaborative Group 2001</a>; <a href="./references#CD007751-bbs2-0120" title="TeoKK , BurtonJR , BullerCE , PlanteS , CatellierD , TymchakW , et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation2000;102(15):1748-54. [MEDLINE: 11023927]">SCAT Study 2000</a>) and ARB (such as LIFE (<a href="./references#CD007751-bbs2-0113" title="LindholmL , IbsenH , DahlofB , DevereuxRB , BeeversG , deFaireU , et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002;359(9311):1004-10. [MEDLINE: 11937179]">Lindholm 2002</a>); SCOPE (<a href="./references#CD007751-bbs2-0114" title="LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension2003;21(5):875-86. [MEDLINE: 12714861]">Lithell 2003</a>)) conducted in people with hypertension or CVD may also include people who meet the criteria of CKD stage 1 to 3 that would potentially enable subgroup or individual patient data analysis. </p> <p>There is a need for further RCTs to be conducted that focus on patients with stage 1 to 3 CKD. These studies should feature designs that are adequate in size and duration, include quality of life outcomes and establish recruitment criteria to ensure that the study population can be generalised to the wider community. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007751-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007751-sec-0008"></div> <div class="table" id="CD007751-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors versus placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ACEi versus placebo for early (stage 1 to 3) non‐diabetic CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with early (stage 1 to 3) non‐diabetic CKD </p> <p><b>Settings:</b> hospitals </p> <p><b>Intervention:</b> ACEi (benazepril 10 mg or trandolapril 2 mg) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ACEi</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Death (any cause)</b> </p> <p>Follow‐up: 3 to 4.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 2 and 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 2.00</b> </p> <p>(0.26 to 15.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>8873 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>76 per 1000</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>152 per 1000</b><br/>(20 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>CVD events: total (fatal and non‐fatal)</b> </p> <p>Follow‐up: 3 to 4.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 2 and 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.97</b> </p> <p>(0.90 to 1.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>8873 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>214 per 1000</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>207 per 1000</b><br/>(192 to 224) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Adverse events: number reporting an adverse event</b> </p> <p>Follow‐up: 3.6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 2 and 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.33</b> </p> <p>(1.26 to 1.41)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>8873 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>304 per 1000</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>405 per 1000</b><br/>(383 to 429) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kidney failure progression: doubling of SCr (mg/dL)</b> </p> <p>Follow‐up: not available</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ACEi:</b> angiotensin‐converting enzyme inhibitor; <b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>CVD:</b> cardiovascular disease; <b>RR:</b> risk ratio; <b>SCr</b>: serum creatinine </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded once (‐1) for serious limitations in the execution (due to risk of bias) </p> <p><sup>2</sup> Downgraded once (‐1) for indirectness, likely related to variability within subgroups due to historical definitions of CKD stages </p> <p><sup>3</sup> No meta‐analysed data from included studies. No GRADE rating for this outcome </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007751-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Angiotensin receptor blockers versus placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ARB versus placebo for early (stage 1 to 3) non‐diabetic CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with early (stage 1 to 3) non‐diabetic CKD </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> ARB (losartan 50 mg) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARB</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Death (any cause)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not estimable</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>226 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>No data<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CVD events</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No data<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Adverse events (number reporting an adverse event)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 19.34</b> </p> <p>(1.14 to 328.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>226 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/><b>very low<sup>2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Kidney failure progression: eGFR (mL/min/1.73m</b> ²<b>)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>226 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/><b>very low<sup>2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was <b>5 mL/min/1.73 m² higher in the ARB group</b> (3.03 higher to 6.97 higher) compared to the placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ARB:</b> angiotensin receptor blockers; <b>CI:</b> confidence interval; <b>CKD:</b> chronic kidney disease; <b>CVD:</b> cardiovascular disease; <b>eGFR:</b> estimated glomerular filtration rate; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No meta‐analysed data from included studies. No GRADE rating for this outcome </p> <p><sup>2</sup> Downgraded once (‐1) for serious limitations in the execution (due to risk of bias) </p> <p><sup>3</sup> Downgraded once (‐1) for sparse data: one study only </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007751-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors versus angiotensin receptor blockers for early (stage 1 to 3) non‐diabetic chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ACEi versus ARB for early (stage 1 to 3) non‐diabetic CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with early (stage 1 to 3) non‐diabetic CKD </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention A:</b> ACEi (enalapril 20 mg, perindopril 2 mg, trandolapril 1 mg) </p> <p><b>Intervention B:</b> ARB (olmesartan 20 mg, losartan 25 mg, candesartan 4 mg) </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARB</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ACEi</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death (any cause)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CVD events</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kidney failure progression</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ACEi:</b> angiotensin‐converting enzyme inhibitor; <b>ARB:</b> angiotensin II receptor blockers; <b>CI:</b> Confidence interval; <b>CVD:</b> cardiovascular disease. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No meta‐analysed data from included studies. No GRADE rating for this outcome </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007751-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007751-sec-0009"></div> <section id="CD007751-sec-0010"> <h3 class="title" id="CD007751-sec-0010">Description of the condition</h3> <p>Chronic kidney disease (CKD) is a long‐term condition that occurs as a result of damage to the kidneys. Prevalence estimates for CKD vary substantially. Several large, high‐quality, population‐based screening studies have reported the prevalence of CKD stage 3 to 5 disease to be around 3.8% to 4.7%; more than 95% of people with an estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m² have stage 3 disease (<a href="./references#CD007751-bbs2-0091" title="CoreshJ , Byrd-HoltD , AstorBC , BriggsJP , EggersPW , LacherDA , et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. Journal of the American Society of Nephrology2005;16(1):180-8. [MEDLINE: 15563563]">Coresh 2005</a>; <a href="./references#CD007751-bbs2-0094" title="DreyN , RoderickP , MulleeM , RogersonM . A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. American Journal of Kidney Diseases2003;42(4):677-84. [MEDLINE: 14520617]">Drey 2003</a>; <a href="./references#CD007751-bbs2-0100" title="HallanSI , DahlK , OienCM , GrootendorstDC , AasbergA , HolmenJ , et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ2006;333(7577):1047. [MEDLINE: 17062598]">Hallan 2006</a>). In most epidemiological studies, the GFR is estimated from serum creatinine (SCr) measurements using an equation; several equations exist, and this contributes to the variation in prevalence reported in these studies. The prevalence of stage 1 and 2 disease is based on microalbuminuria (albumin:creatinine ratio (ACR) of 17 to 250 mg/g for men or 25 to 355 mg/g for women) or macroalbuminuria (ACR &gt; 250 mg/g for men or &gt; 355 mg/g for women) has been reported to be as high as 11% of the population (<a href="./references#CD007751-bbs2-0089" title="Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR - Morbidity &amp; Mortality Weekly Report2007;56(8):161-5. [MEDLINE: 17332726]">CDC 2007</a>). The prevalence of CKD increases with age (<a href="./references#CD007751-bbs2-0091" title="CoreshJ , Byrd-HoltD , AstorBC , BriggsJP , EggersPW , LacherDA , et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. Journal of the American Society of Nephrology2005;16(1):180-8. [MEDLINE: 15563563]">Coresh 2005</a>; <a href="./references#CD007751-bbs2-0100" title="HallanSI , DahlK , OienCM , GrootendorstDC , AasbergA , HolmenJ , et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ2006;333(7577):1047. [MEDLINE: 17062598]">Hallan 2006</a>; <a href="./references#CD007751-bbs2-0104" title="ImaiE , HorioM , IsekiK , YamagataK , WatanabeT , HaraS , et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clinical &amp; Experimental Nephrology2007;11(2):156-63. [MEDLINE: 17593516]">Imai 2007</a>; <a href="./references#CD007751-bbs2-0107" title="JohnR , WebbM , YoungA , StevensPE . Unreferred chronic kidney disease: a longitudinal study. American Journal of Kidney Diseases2004;43(5):825-35. [MEDLINE: 15112173]">John 2004</a>). An ageing population, escalating prevalence of diabetes mellitus (DM) (one of the major risk factors for CKD), and increasing recognition are contributing to a reported increase in the prevalence of early CKD and its growing recognition as a major public health problem. </p> <p>In 2002, the US Kidney Disease Outcomes Quality Initiative (KDOQI) proposed a classification for CKD that has been widely adopted internationally (<a href="./references#CD007751-bbs2-0112" title="LeveyAS , CoreshJ , BalkM , KauszAT , LevinA , SteffesMW , et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine2003;139(2):137-47. [MEDLINE: 12859163]">Levey 2003</a>). In 2012, the 2002 KDOQI CKD guidelines were updated by The KDIGO CKD Guideline Development Work Group to the KDIGO 2012 CKD classifications (<a href="./references#CD007751-bbs2-0126" title="StevensPE , LevinA , Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the Kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of Internal Medicine2013;158(11):825-30. [MEDLINE: 23732715]">Stevens 2013</a>). See <a href="./appendices#CD007751-sec-0113">Appendix 1</a> for full details of the KDIGO 2012 CKD classifications. </p> <p>Early CKD, whilst often asymptomatic, is an important health issue and has implications for individuals and health services. Progressive deterioration of kidney function can result in end‐stage kidney disease (ESKD) and the need for kidney replacement therapy (KRT) in the form of dialysis or transplantation. The rate of progression of CKD may be influenced by secondary factors such as age, race, intraglomerular haemodynamic factors, hypertension and proteinuria. ESKD has risen globally over the last two decades at a high cost to individuals, their carers and families, and health services. However, the proportion of people with early CKD who progress to ESKD is low (<a href="./references#CD007751-bbs2-0092" title="DalyC . Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrology Dialysis Transplantation2007;22 Suppl 9:ix19-25. [MEDLINE: 17998227]">Daly 2007</a>; <a href="./references#CD007751-bbs2-0100" title="HallanSI , DahlK , OienCM , GrootendorstDC , AasbergA , HolmenJ , et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ2006;333(7577):1047. [MEDLINE: 17062598]">Hallan 2006</a>). A greater risk for people with early CKD is cardiovascular disease (CVD). One study that followed patients over a period of five years, reported that 3.1% of people with CKD progressed to requiring KRT, whereas 24.9% died before reaching dialysis, probably as a result of CVD (<a href="./references#CD007751-bbs2-0092" title="DalyC . Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrology Dialysis Transplantation2007;22 Suppl 9:ix19-25. [MEDLINE: 17998227]">Daly 2007</a>). </p> <p>Early recognition and management of CKD affords the opportunity not only to prepare for progressive kidney impairment and impending KRT (<a href="./references#CD007751-bbs2-0090" title="AstorBC , EustaceJA , PoweNR , KlagMJ , SadlerJH , FinkNE , et al. The timing of nephrologist referral and arteriovenous access use: the CHOICE study. American Journal of Kidney Diseases2001;38(3):494-501. [MEDLINE: 11532680]">CHOICE Study 2001</a>; <a href="./references#CD007751-bbs2-0093" title="DoganE , ErkocR , SayarliogluH , DurmusA , TopalC . Effects of late referral to a nephrologist in patients with chronic renal failure. Nephrology2005;10(5):516-9. [MEDLINE: 16221105]">Dogan 2005</a>; <a href="./references#CD007751-bbs2-0108" title="KhanS , Amedia CA Jr. Economic burden of chronic kidney disease. Journal of Evaluation in Clinical Practice2007;14(3):422-34. [MEDLINE: 18373575]">Khan 2007</a>; <a href="./references#CD007751-bbs2-0109" title="KinchenKS , SadlerJ , FinkN , BrookmeyerR , KlagMJ , LeveyAS , et al. The timing of specialist evaluation in chronic kidney disease and mortality. Annals of Internal Medicine2002;137(6):479-86. [MEDLINE: 12230348]">Kinchen 2002</a>) but also for intervening to reduce the risk of progression and CVD. </p> </section> <section id="CD007751-sec-0011"> <h3 class="title" id="CD007751-sec-0011">Description of the intervention</h3> <p>Angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are two classes of antihypertensive drugs that act on the renin‐angiotensin‐aldosterone system (RAAS). Both drug classes have been widely recommended in guidelines for the management of CKD, particularly in patients with evidence of proteinuria, and have been reported to provide both cardioprotective and renoprotective effects. Beneficial effects of ACEi and ARB on kidney outcomes and survival in people with diabetic kidney disease (DKD) have been reported (<a href="./references#CD007751-bbs2-0127" title="StrippoliGF , BonifatiC , CraigM , NavaneethanSD , CraigJC . Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD006257. [DOI: 10.1002/14651858.CD006257]">Strippoli 2006</a>). For patients with moderate to severe CKD without diabetes, there was evidence of benefit in terms of kidney outcomes whether or not proteinuria was present (<a href="./references#CD007751-bbs2-0106" title="JafarTH , StarkPC , SchmidCH , LandaM , MaschioG , deJongPE , et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria and angiotensin-converting enzyme inhibition: proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Annals of Internal Medicine2003;139(4):244-53. [MEDLINE: 12965979]">Jafar 2003a</a>). The evidence for cardioprotective effects, particularly in patients with CKD without diabetes, is less consistent (<a href="./references#CD007751-bbs2-0088" title="DahlofB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet2005;366(9489):895-906. [MEDLINE: 16154016]">ASCOT‐BPLA Study 2005</a>; <a href="./references#CD007751-bbs2-0103" title="Heart Outcomes Prevention Evaluation Study Investigators, YusufS , SleightP , PogueJ , BoschJ , DaviesR , et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [Erratum in: 2000 May 4;342(18):1376] [Erratum in: N Engl J Med 2000 Mar 9;342(10):748]. New England Journal of Medicine2000;342(3):145-53. [MEDLINE: 10639539]">HOPE Study 1996</a>; <a href="./references#CD007751-bbs2-0127" title="StrippoliGF , BonifatiC , CraigM , NavaneethanSD , CraigJC . Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD006257. [DOI: 10.1002/14651858.CD006257]">Strippoli 2006</a>). </p> <p>To date, reviews have combined evidence from study participants with a wide range of severity of kidney impairment, but the subgroup of those with early CKD (stage 1 to 3) has not been presented separately. </p> </section> <section id="CD007751-sec-0012"> <h3 class="title" id="CD007751-sec-0012">How the intervention might work</h3> <p>As kidneys become damaged and begin to lose nephrons, patients experience systemic hypertension, proteinuria and a progressive decline in eGFR (<a href="./references#CD007751-bbs2-0116" title="MetcalfeW . How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrology Dialysis Transplantation2007;22 Suppl 9:ix26-30. [MEDLINE: 17998229]">Metcalfe 2007</a>). Common pathological changes are observed regardless of the underlying causes and include early kidney inflammation; tubulointerstitial injury, and glomerulosclerosis (<a href="./references#CD007751-bbs2-0119" title="RusterC , WolfG . Renin-angiotensin-aldosterone system and progression of renal disease. Journal of the American Society of Nephrology2006;17(11):2985-91. [MEDLINE: 17035613]">Ruster 2006</a>). The pathophysiology of progressive kidney function loss involves complex haemodynamic, endocrine, and inflammatory factors (<a href="./references#CD007751-bbs2-0116" title="MetcalfeW . How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrology Dialysis Transplantation2007;22 Suppl 9:ix26-30. [MEDLINE: 17998229]">Metcalfe 2007</a>; <a href="./references#CD007751-bbs2-0119" title="RusterC , WolfG . Renin-angiotensin-aldosterone system and progression of renal disease. Journal of the American Society of Nephrology2006;17(11):2985-91. [MEDLINE: 17035613]">Ruster 2006</a>). </p> <p>ACEi and ARB both act to inhibit the RAAS endocrine system. ACEi mode of action includes blocking the conversion of inactive angiotensin I to active angiotensin II at the level of the enzyme needed for its conversion. ARB works at a later stage in the RAAS system and selectively blocks the type I subtype, which is a receptor for angiotensin II (<a href="./references#CD007751-bbs2-0111" title="KumarPJ , ClarkML . Kumar &amp; Clark clinical medicine. 5th edition. Edinburgh: WB Saunders, 2002. [ISBN: 0702025798]">Kumar 2002</a>). Once thought of as a systemic endocrine system important in mediating vascular tone, RAAS is now understood to be complex, operating both systemically and locally within the kidney. Products of the RAAS are understood to impact a wide range of kidney, as well as haemodynamic, factors that contribute to the progression of CKD (<a href="./references#CD007751-bbs2-0110" title="KshirsagarAV , JoyMS , HoganSL , FalkRJ , ColindresRE . Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. American Journal of Kidney Diseases2000;35(4):695-707. [MEDLINE: 10739792]">Kshirsagar 2000a</a>; <a href="./references#CD007751-bbs2-0111" title="KumarPJ , ClarkML . Kumar &amp; Clark clinical medicine. 5th edition. Edinburgh: WB Saunders, 2002. [ISBN: 0702025798]">Kumar 2002</a>; <a href="./references#CD007751-bbs2-0119" title="RusterC , WolfG . Renin-angiotensin-aldosterone system and progression of renal disease. Journal of the American Society of Nephrology2006;17(11):2985-91. [MEDLINE: 17035613]">Ruster 2006</a>). </p> <p>The action of ACEi and ARB extends beyond simple blood pressure (BP) control and may reflect effects on the complex RAAS pathways. The ability of both of these drugs to inhibit the RAAS at different points means that they have the potential to moderate the functional and structural changes that occur in progressive kidney insufficiency (<a href="./references#CD007751-bbs2-0095" title="GiatrasI , LauJ , LeveyAS . Effect of angiotensin converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Annals of Internal Medicine1997;127(5):337-45. [MEDLINE: 9273824]">Giatras 1997a</a>; <a href="./references#CD007751-bbs2-0106" title="JafarTH , StarkPC , SchmidCH , LandaM , MaschioG , deJongPE , et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria and angiotensin-converting enzyme inhibition: proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Annals of Internal Medicine2003;139(4):244-53. [MEDLINE: 12965979]">Jafar 2003a</a>; <a href="./references#CD007751-bbs2-0110" title="KshirsagarAV , JoyMS , HoganSL , FalkRJ , ColindresRE . Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. American Journal of Kidney Diseases2000;35(4):695-707. [MEDLINE: 10739792]">Kshirsagar 2000a</a>). </p> </section> <section id="CD007751-sec-0013"> <h3 class="title" id="CD007751-sec-0013">Why it is important to do this review</h3> <p>Early recognition of CKD is becoming increasingly common due to widespread laboratory reporting of eGFR, raised clinical awareness, and international adoption of the KDIGO classification. The high prevalence of early CKD means that many individuals and clinicians are faced with choices about management. Another Cochrane review (<a href="./references#CD007751-bbs2-0127" title="StrippoliGF , BonifatiC , CraigM , NavaneethanSD , CraigJC . Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD006257. [DOI: 10.1002/14651858.CD006257]">Strippoli 2006</a>) has reviewed the evidence of effectiveness in people with diabetic CKD and demonstrated that ACEi and ARB play a core role in the management and prevention of DKD, where proteinuria is a key feature. For people without diabetes, particularly those with normal or mild to moderate kidney function impairment where proteinuria may or may not be present, the role of ACEi and ARB is less certain. This is an update of a review last published in 2011 (<a href="./references#CD007751-bbs2-0130" title="SharmaP , BlackburnRC , ParkeCL , McCulloughK , MarksA , BlackC . Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database of Systematic Reviews2011, Issue 10. Art. No: CD007751. [DOI: 10.1002/14651858.CD007751.pub2]">Sharma 2011</a>) that seeks to summarise the evidence in relation to the benefits and harms of ACEi and ARB for patients with early (stage 1 to 3) CKD without diabetes. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007751-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007751-sec-0014"></div> <p>To evaluate the benefits and harms of ACEi and ARB in the management of people with early (stage 1 to 3) CKD without DM. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007751-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007751-sec-0015"></div> <section id="CD007751-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007751-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (studies in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at the effect of ACEi or ARB were included. The first period of randomised cross‐over studies was considered for inclusion. Only studies of at least four weeks duration were included to show that any effects of RAAS therapy occur beyond haemodynamic changes at the introduction of new antihypertensive therapies. </p> </section> <section id="CD007751-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD007751-sec-0019"> <h5 class="title">Inclusion criteria</h5> <p>All adults (18 years or over) with early CKD without DM, with no restriction to gender or race, were considered. Early CKD was defined as KDIGO stages 1 to 3 (<a href="./references#CD007751-bbs2-0126" title="StevensPE , LevinA , Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the Kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of Internal Medicine2013;158(11):825-30. [MEDLINE: 23732715]">Stevens 2013</a>; <a href="./appendices#CD007751-sec-0113">Appendix 1</a>). We included studies that measured GFR by any method (excretion of iohexol, inulin or similar marker; estimated from 24‐hour urine collection; or estimated from SCr using a recognised equation). </p> <p>Studies defining CKD based on SCr or other thresholds of eGFR were included in the review if the results had been presented separately for those with KDIGO stages 1 to 3. Studies in general populations that included people with DM were kept in the review if the results were presented separately for those with and without DM. If the results were not presented separately, and less than 30% of the study population had DM, the study was included, and the effect on the outcomes was assessed with a sensitivity analysis. The same process was adopted for study populations that included people with specific renal pathologies (e.g. immunoglobulin A (IgA) nephropathy, lupus nephritis, polycystic kidney disease). </p> </section> <section id="CD007751-sec-0020"> <h5 class="title">Exclusion criteria</h5> <p>Any studies of patients with a diagnosis of DM (type I or II) were excluded. Because the prognosis for people with specific kidney diagnoses cannot be generalised to the wider population with CKD, studies restricted to patients with a single specific kidney diagnosis (e.g. IgA nephropathy, lupus nephritis, polycystic kidney disease) were excluded. </p> </section> </section> <section id="CD007751-sec-0021"> <h4 class="title">Types of interventions</h4> <p>All ACEi and ARB or combinations were included as outlined below:</p> <p> <ol id="CD007751-list-0001"> <li> <p>Treatment with ACEi versus placebo</p> </li> <li> <p>Treatment with ARB versus placebo</p> </li> <li> <p>Treatment with ACEi plus ARB versus placebo</p> </li> <li> <p>Treatment with ACEi versus ARB</p> </li> </ol> </p> <p>The ACEi class includes the following:</p> <p> <ul id="CD007751-list-0002"> <li> <p>Benazepril</p> </li> <li> <p>Captopril</p> </li> <li> <p>Cilazapril</p> </li> <li> <p>Delapril</p> </li> <li> <p>Enalapril maleate</p> </li> <li> <p>Fosinopril sodium</p> </li> <li> <p>Imidapril hydrochloride</p> </li> <li> <p>Lisinopril</p> </li> <li> <p>Moexipril hydrochloride</p> </li> <li> <p>Perindopril erbumine</p> </li> <li> <p>Quinapril</p> </li> <li> <p>Ramipril</p> </li> <li> <p>Spirapril</p> </li> <li> <p>Trandolapril</p> </li> <li> <p>Zofenopril</p> </li> </ul> </p> <p>The ARB class includes the following:</p> <p> <ul id="CD007751-list-0003"> <li> <p>Candesartan</p> </li> <li> <p>Eprosartan</p> </li> <li> <p>Irbesartan</p> </li> <li> <p>Losartan</p> </li> <li> <p>Olmesartan</p> </li> <li> <p>Telmisartan</p> </li> <li> <p>Valsartan</p> </li> <li> <p>Azilsartan</p> </li> </ul> </p> <p>Any dose and dosing regimen were included in the review. Combination preparations with medicines other than ACEi and ARB were not included. Only oral preparations were included. </p> <p>As they are licensed, new drugs will be added to the review in subsequent updates.</p> </section> <section id="CD007751-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD007751-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007751-list-0004"> <li> <p>Death (any cause)</p> </li> <li> <p>CVD events, including total CVD events (fatal and non‐fatal), death, stroke, myocardial infarction (MI), cerebrovascular accident, congestive heart failure, and transient ischaemic attack (TIA)) </p> </li> <li> <p>ESKD including KRT</p> </li> </ol> </p> </section> <section id="CD007751-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007751-list-0005"> <li> <p>Quality of life (QoL) measured by a visual analogue scale, such as SF‐36 and KDQoL</p> </li> <li> <p>Adverse events including but not limited to: allergic reactions, cough, headache, hyperkalaemia, hypotension, angioedema, and acute kidney injury (AKI) </p> </li> <li> <p>Kidney failure progression defined by: eGFR, doubling of SCr, progression of CKD stage</p> </li> <li> <p>Proteinuria and albuminuria including: progression of microalbuminuria to macroalbuminuria, regression of macroalbuminuria to microalbuminuria, progression of normo‐albuminuria to microalbuminuria, regression of microalbuminuria to normo‐albuminuria measured by urinary protein:creatinine ratio (UPCR) (mg/mmol); urinary total protein excretion (g/24 hours); urinary ACR (mg/mmol); urinary albumin excretion (µg/min) </p> </li> <li> <p>BP (mm Hg) including: total BP, systolic (S) BP or diastolic (D) BP (reported as mean change from baseline or percentage reaching study‐specific target) </p> </li> <li> <p>Costs: total healthcare costs</p> </li> <li> <p>Hospital admission rates</p> </li> <li> <p>Falls</p> </li> <li> <p>Fatigue</p> </li> <li> <p>Dementia</p> </li> </ol> </p> </section> </section> </section> <section id="CD007751-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007751-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 6 July 2023 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources. </p> <p> <ol id="CD007751-list-0006"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Searches of kidney and transplant journals and the proceedings and abstracts from major kidney and transplant conferences </p> </li> <li> <p>Searching the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov. </p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the <a href="https://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant website</a>. </p> <p>See <a href="./appendices#CD007751-sec-0114">Appendix 2</a> for search terms used in strategies for this review. </p> </section> <section id="CD007751-sec-0027"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD007751-list-0007"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Contacting relevant individuals/organisations seeking information about unpublished or incomplete studies. </p> </li> <li> <p>Grey literature sources (e.g. abstracts, dissertations and theses), in addition to those already included in the Cochrane Kidney and Transplant Register of Studies, were not searched. </p> </li> </ol> </p> </section> </section> <section id="CD007751-sec-0028"> <h3 class="title" id="CD007751-sec-0028">Data collection and analysis</h3> <section id="CD007751-sec-0029"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies potentially relevant to the review. The titles and abstracts were screened independently by two authors who discarded the studies that did not meet the inclusion criteria, although studies and reviews that might include relevant data or information on trials were retained initially. Two authors independently assessed the abstracts and, whenever necessary, the full text of these studies to determine which studies satisfied the inclusion criteria. </p> </section> <section id="CD007751-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out by the same authors independently using a standard data extraction form. Studies reported in non‐English language journals we planned to translate before assessment; none of the included studies required translation. Where more than one publication of one study existed, reports were grouped together, and all relevant data was included. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancy between published versions was to be highlighted. Where further information was required from the original investigator, attempts were made for additional data requested by written correspondence, and any relevant information obtained in this manner was to be included in the review. Disagreements were resolved in consultation with a third author. </p> </section> <section id="CD007751-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were assessed independently by two authors using the risk of bias assessment tool (<a href="./references#CD007751-bbs2-0102" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>) (see <a href="./appendices#CD007751-sec-0115">Appendix 3</a>). </p> <p> <ul id="CD007751-list-0008"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD007751-list-0009"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at risk of bias?</p> </li> </ul> </p> </section> <section id="CD007751-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. death, cardiovascular morbidity, adverse events), results were expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (e.g. SCr), the mean difference (MD) was used. According to the protocol, the standardised mean difference (SMD) was to be used where different scales had been applied. In instances where change from baseline data (change scores) were reported, the difference in mean change scores was to be used. It was planned that if standard deviations (SDs) for change scores were not available, missing data were not to be imputed. Data were presented in tabular form, and where appropriate, final score data and change from baseline were incorporated into meta‐analyses. If adjustment had been undertaken to account for baseline values, these data were to be reported. Time‐to‐event data (e.g. survival, time to ESKD) were to be analysed as a dichotomous variable where data were presented for all participants up to a specified time period. Alternatively, hazard ratios (and 95% CI) were to be used, with the application of the proportional hazard assumption, for the purpose of comparison and meta‐analysis (<a href="./references#CD007751-bbs2-0102" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD007751-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We did not anticipate that there would be any non‐standard designs, such as cross‐over studies and cluster‐RCTs, but multiple arm studies could be identified. Here, all intervention groups relevant to the review were included. It was planned that if there were several relevant comparisons, all independent comparisons were to be included. It was also planned that if a comparator group overlapped (such as a single placebo arm), either comparison groups would be combined (if appropriate), or only the most important comparison would be selected for meta‐analysis. </p> </section> <section id="CD007751-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>Intention‐to‐treat was the primary analysis sought from studies. Missing outcomes data and the implications were discussed, but the imputation of missing data was not undertaken. Attempts to contact the original authors for additional outcome data were made. No such data were obtained. </p> </section> <section id="CD007751-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We then quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<a href="./references#CD007751-bbs2-0101" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). A guide to the interpretation of I² values was as follows. </p> <p> <ul id="CD007751-list-0010"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I² depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi² test or a CI for I²) (<a href="./references#CD007751-bbs2-0102" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD007751-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>It was planned that funnel plots were to be assessed for evidence of publication bias and to plot effect estimates against study size where data permitted. </p> </section> <section id="CD007751-sec-0037"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model, but the fixed‐effects model was also analysed to ensure the robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD007751-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where data were available, subgroup analysis was undertaken to explore possible sources of heterogeneity related to the following characteristics: </p> <p> <ul id="CD007751-list-0011"> <li> <p>CKD stage</p> </li> <li> <p>Presence of microalbuminuria/proteinuria.</p> </li> </ul> </p> <p>The remaining characteristics were planned; however, no such data were available:</p> <p> <ul id="CD007751-list-0012"> <li> <p>Age and sex</p> </li> <li> <p>Comorbidities (CVD, hypertension)</p> </li> <li> <p>Distribution of underlying renal pathologies</p> </li> <li> <p>Interventions (heterogeneity in treatments could be related to prior agent(s) used and the agent, dose and duration of therapy) </p> </li> <li> <p>Study quality.</p> </li> </ul> </p> <p>Adverse effects were tabulated and assessed with descriptive techniques because they were likely to be different for the various agents used. Where possible, the risk difference (RD) with 95% CI was to be calculated for each adverse effect, compared with either no treatment or another agent. </p> <p>It was planned that QoL measures would be tabulated and reported descriptively, or if data permitted, meta‐analysis would be undertaken as described. </p> </section> <section id="CD007751-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>It was planned to undertake sensitivity analyses to explore the robustness of findings to key decisions in the review process. These were to be determined as the review process took place(<a href="./references#CD007751-bbs2-0102" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD007751-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the certainty of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD007751-bbs2-0121" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. www.training.cochrane.org/handbook.">Schünemann 2022a</a>). </p> <p>The 'Summary of findings' tables also includes an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD007751-bbs2-0096" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD007751-bbs2-0097" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011a</a>; <a href="./references#CD007751-bbs2-0098" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso-CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311-6. [MEDLINE: 21802902]">GRADE 2011b</a>). The GRADE approach defines the certainty of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The certainty of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD007751-bbs2-0122" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022b</a>). See <a href="./appendices#CD007751-sec-0116">Appendix 4</a> for details on how GRADE was assessed and applied to the evidence found in this review. </p> <p>We presented the following outcomes, where data were available, in the 'Summary of findings' tables: </p> <p> <ul id="CD007751-list-0013"> <li> <p>Death (any cause)</p> </li> <li> <p>CVD events</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Kidney failure progression: doubling of SCr</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007751-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007751-sec-0041"></div> <section id="CD007751-sec-0042"> <h3 class="title">Description of studies</h3> <p>The following section contains broad descriptions of the studies considered in this review. For further details on each individual study please see the characteristics of studies table <a href="./references#CD007751-sec-0127" title="">Characteristics of included studies</a> and <a href="./references#CD007751-sec-0128" title="">Characteristics of excluded studies</a>. </p> <section id="CD007751-sec-0043"> <h4 class="title">Results of the search</h4> <p>A search of the Cochrane Kidney and Transplant Specialised Register of Studies on 6 July 2023 identified 244 new reports. A full‐text assessment identified 28 new studies, of which two new studies (2 reports) were included (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>) and 26 (112 reports) were excluded. Seven potential studies (9 reports) were identified prior to publication and will be assessed in a future update of this review. </p> <p>A total of six studies (45 reports, 9379 participants, <a href="#CD007751-fig-0001">Figure 1</a>) were included, and 73 studies were excluded in this review. </p> <div class="figure" id="CD007751-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram" data-id="CD007751-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram</p> </div> </div> </div> </section> <section id="CD007751-sec-0044"> <h4 class="title">Included studies</h4> <p>Six studies (9379 randomised participants) met our inclusion criteria (<a href="./references#CD007751-sec-0127" title="">Characteristics of included studies</a>). </p> <p>Of these, three were single‐centre studies (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>; <a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>), and three were multi‐centre studies (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>; <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>), and all took place in a hospital setting. Studies were undertaken in Canada, China, France, Germany, Italy, Japan, Puerto Rico, Spain and the USA. </p> <p>Sample sizes ranged from 30 participants (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>) to 8290 participants (<a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>). </p> <p>Participants were adults with CKD stages G1 and G2 (<a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>), G2 (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>), and G3b (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>). <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a> included participants with CKD stages 1 to 4. </p> <p>Five studies compared two parallel arms, and one study was a cross‐over which did not report separate data for the first phase of the trial (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>). Three studies compared ACEi to placebo (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>; <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>), one study compared ARB to placebo (<a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>), and two studies compared ACEi to ARB (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>; <a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>). Treatment periods ranged from 12 weeks (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>) to 3 years (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>). </p> </section> <section id="CD007751-sec-0045"> <h4 class="title">Excluded studies</h4> <p>For this update, we reassessed all previously excluded studies. One study was merged with an existing included study (<a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>), and two studies were merged with existing excluded studies (<a href="./references#CD007751-bbs2-0034" title="IhleB , BeckerG , WhitworthJ , ShahinfarS , CnaanA , Kincaid-SmithP . The effect of angiotensin converting enzyme inhibition (ACEi) on progression of chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology1992;3(3):284. [CENTRAL: CN-00460980] IhleBU , WhitworthJA , ShahinfarS , CnaanA , Kincaid-SmithPS , BeckerGJ . Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. American Journal of Kidney Diseases1996;27(4):489-95. [MEDLINE: 8678058]">Ihle 1996</a>; <a href="./references#CD007751-bbs2-0036" title="KannoY , TakenakaT , NakamuraT , SuzukiH . Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clinical Journal of the American Society of Nephrology: CJASN2006;1(4):730-7. [MEDLINE: 17699280]KannoY , TakenakaT , NakamuraT , SuzukiH . Add-on angiotensin receptor blocker in patients with chronic kidney diseases treated with angiotensin converting enzyme inhibitors [abstract no: SA-FC104]. Journal of the American Society of Nephrology2005;16:105A. [CENTRAL: CN-00626068] ">Kanno 2006</a>). We deleted 42 studies: 27 studies were not randomised, 11 studies were the wrong or mixed population, and four studies used the wrong intervention or comparator. </p> <p>For the 2023 search, we excluded 26 new studies (112 reports) and identified 93 new reports of 25 already excluded studies. In total, we have excluded 74 studies (270 reports). </p> <section id="CD007751-sec-0046"> <h5 class="title">Studies awaiting classification</h5> <p>Seven potential studies (9 reports) were identified prior to publication and will be assessed in a future update of this review. </p> </section> <section id="CD007751-sec-0047"> <h5 class="title">Ongoing studies</h5> <p>There are no ongoing studies.</p> </section> </section> </section> <section id="CD007751-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD007751-fig-0002">Figure 2</a> and <a href="#CD007751-fig-0003">Figure 3</a> for a graphical summary of the risk of bias assessment within each study. </p> <div class="figure" id="CD007751-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007751-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD007751-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD007751-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <p>Most studies were characterised by an unclear to high risk of bias across the domains, mostly pertaining to a lack of sufficient detail provided regarding methodology, lack of blinding, or industry funding. Using funnel plots to detect publication bias was not feasible because of the small number of studies included in this review. </p> <section id="CD007751-sec-0049"> <h4 class="title">Allocation</h4> <section id="CD007751-sec-0050"> <h5 class="title">Random sequence generation</h5> <p>Two studies were judged to have an unclear risk of bias due to a lack of information provided on randomisation methods within the text, although they were stated to be randomised (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>). </p> <p>Four studies were judged to have a low risk of bias for providing an adequate description of how their randomisation methods were undertaken, such as permuted blocks on a 1 to 1 basis, sealed envelopes, or a computerised random number generator (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>; <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>). </p> </section> <section id="CD007751-sec-0051"> <h5 class="title">Allocation concealment</h5> <p>Two studies were open‐label and judged to have a high risk of bias (<a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>). </p> <p>Two studies were judged to have an unclear risk of bias due to a lack of information provided on how allocation was concealed for the intervention arms (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>). </p> <p>Two studies judged to have a low risk of bias; they reported that only a third party knew the treatment allocations (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>; <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>). </p> </section> </section> <section id="CD007751-sec-0052"> <h4 class="title">Blinding</h4> <section id="CD007751-sec-0053"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>Two studies were open‐label and judged to have a high risk of bias (<a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>). </p> <p>Two studies were judged to have an unclear risk of bias due to not providing any details as to how any blinding of personnel took place (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>). </p> <p>Two studies judged to have a low risk of bias for describing that only a third part knew the treatment groups (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>; <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>). </p> </section> <section id="CD007751-sec-0054"> <h5 class="title">Blinding of outcome assessors (detection bias)</h5> <p>Two studies were open‐label and judged to have a high risk of bias (<a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>). </p> <p>Four studies were judged to have an unclear risk of bias due to not providing any details as to how any blinding of the outcome assessors took place (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>; <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>). </p> </section> </section> <section id="CD007751-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies were judged to have a high risk of bias due to a high attrition rate (43%) or missing data on withdrawals and completers (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>; <a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>; <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>). </p> <p>Three studies were judged to have an unclear risk of bias due to low attrition (6%) but with some unclear details of completers or moderate attrition (23% to 25%) (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>). </p> </section> <section id="CD007751-sec-0056"> <h4 class="title">Selective reporting</h4> <p>Five studies were judged to have an unclear risk of bias due to no information being available on trial registration or an a priori published protocol (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>; <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>). </p> <p>One study was judged to have a low risk of bias due to an available pre‐registered trial registration number (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>). </p> </section> <section id="CD007751-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>Five studies were judged to have a high risk of bias due to pharmaceutical industry funding (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>; <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>), or traditional Chinese medicine (TMC) industry funding (<a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>). </p> <p>One study was judged to have an unclear risk of bias as it did not report the sources of funding (<a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>). </p> <p>Four studies did not report if there were any conflicts of interest (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>; <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>). Of the two studies that did report their conflicts of interest, <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a> reported financial collaboration with the pharmaceutical industry. </p> </section> </section> <section id="CD007751-sec-0058"> <h3 class="title" id="CD007751-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD007751-tbl-0001"><b>Summary of findings 1</b> Angiotensin‐converting enzyme inhibitors versus placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease</a>; <a href="./full#CD007751-tbl-0002"><b>Summary of findings 2</b> Angiotensin receptor blockers versus placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease</a>; <a href="./full#CD007751-tbl-0003"><b>Summary of findings 3</b> Angiotensin‐converting enzyme inhibitors versus angiotensin receptor blockers for early (stage 1 to 3) non‐diabetic chronic kidney disease</a> </p> <section id="CD007751-sec-0059"> <h4 class="title">Angiotensin‐converting enzyme inhibitors versus placebo</h4> <p>Three studies compared an ACEi with placebo, in people who have CKD stage 2 or 3, over a 36 to 63‐month treatment period. </p> <p> <ul id="CD007751-list-0014"> <li> <p><a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>: benazepril 10 mg/day </p> </li> <li> <p><a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>: trandolapril 2 mg/day </p> </li> <li> <p><a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>: ramipril 1.25 mg/day titrated to 5 mg </p> </li> </ul> </p> <p><a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a> investigated participants with CKD stages 1 to 4 with no separate data reported for the participants with early CKD stages 1 to 3. The results have been reported narratively. </p> <p>See <a href="./full#CD007751-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD007751-sec-0060"> <h5 class="title">Primary outcomes</h5> <section id="CD007751-sec-0061"> <h6 class="title">Death (any cause)</h6> <p>ACEi may make little or no difference in reducing the number of deaths (any cause) at 4.8 years (median follow‐up) compared to placebo (<a href="./references#CD007751-fig-0004" title="">Analysis 1.1</a> (2 studies, 8873 participants): RR 2.00, 95% CI 0.26 to 15.37; I² = 76%; low certainty evidence). </p> <section id="CD007751-sec-0062"> <p><b>Long‐term follow‐up</b></p> <p><a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a> reported no difference in the number of deaths between ACEi and placebo at 6.6 years follow‐up (benazepril 10 mg: 25 in 300; placebo: 23 in 283). <a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a> also reported during the extended follow‐up, 64% of those patients randomised to benazepril continued on an ACEi, and 61% in the placebo arm started treatment with an ACEi. </p> <p>For participants with CKD stages 1 to 4, <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a> reported no difference in the number of deaths at 63 months between ACEi and placebo for participants with CKD stages 1 to 4 (ramipril: 1 in 99; placebo: 0 in 87). </p> </section> </section> <section id="CD007751-sec-0063"> <h6 class="title">Cardiovascular events: total events</h6> <p>ACEi may make little or no difference in reducing the number of total cardiovascular events compared to placebo (<a href="./references#CD007751-fig-0005" title="">Analysis 1.2</a> (2 studies, 8873 participants): RR 0.97, 95% CI 0.90 to 1.05; I² = 0%; low certainty evidence). </p> </section> <section id="CD007751-sec-0064"> <h6 class="title">Cardiovascular disease events: death</h6> <p>ACEi may make little or no difference in reducing the number of cardiovascular‐related deaths compared to placebo at 4.8 years (median follow‐up) (<a href="./references#CD007751-fig-0006" title="">Analysis 1.3</a> (2 studies, 8873 participants): RR 1.73, 95% CI 0.26 to 11.66; I² = 54%; low certainty evidence). </p> <p>For participants with CKD stages 1 to 4, <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a> reported ACEi compared to placebo made no difference to CVD‐related deaths at 63 months (ramipril: 0 in 99; placebo: 0 in 87). </p> </section> <section id="CD007751-sec-0065"> <h6 class="title">Cardiovascular disease events: stroke</h6> <p>ACEi may make little or no difference in reducing the number of strokes compared to placebo at 4.8 years (median follow‐up) (<a href="./references#CD007751-fig-0007" title="">Analysis 1.4</a> (2 studies, 8873 participants): RR 0.76, 95% CI 0.56 to 1.03; I² = 0%; low certainty evidence). </p> <p>For participants with CKD stages 1 to 4, <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a> reported ACEI compared to placebo made no difference to stroke at 63 months (ramipril: 1 in 99; placebo: 0 in 87). </p> </section> <section id="CD007751-sec-0066"> <h6 class="title">Cardiovascular disease events: myocardial infarction</h6> <p>ACEi may make little or no difference in reducing the number of MIs compared to placebo at 4.8 years (median follow‐up) (<a href="./references#CD007751-fig-0008" title="">Analysis 1.5</a> (2 studies, 8873 participants): RR 1.00, 95% CI 0.84 to 1.20; I² = 0%; low certainty evidence). </p> </section> <section id="CD007751-sec-0067"> <h6 class="title">Cardiovascular disease events: congestive heart failure</h6> <p><a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a> reported ACEi may reduce the number of congestive heart failures compared to placebo at 4.8 years (median follow‐up) (<a href="./references#CD007751-fig-0009" title="">Analysis 1.6</a> (1 study, 8290 participants): RR 0.75, 95% CI 0.59 to 0.95; low certainty evidence). </p> <p>For participants with CKD stages 1 to 4, <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a> reported ACEi compared to placebo made no difference to congestive heart failure at 63 months (ramipril: 1 in 99; placebo: 0 in 87). </p> </section> <section id="CD007751-sec-0068"> <h6 class="title">Cardiovascular disease events: transient ischaemic attack</h6> <p>It is uncertain whether ACEi makes a difference in reducing the number of TIAs compared to placebo at 4.8 years (median follow‐up) (<a href="./references#CD007751-fig-0010" title="">Analysis 1.7</a> (1 study, 583 participants): RR 0.94, 95% CI 0.06 to 15.01; very low certainty evidence). </p> </section> <section id="CD007751-sec-0069"> <h6 class="title">End‐stage kidney disease</h6> <p>For participants whose baseline eGFR was &gt; 45 mL/min/1.73 m², <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a> reported no difference in the progression to KRT between ACEi and placebo at 63 months (3 in 101 participants ‐ it was not clear from which groups these participants came). </p> </section> </section> <section id="CD007751-sec-0070"> <h5 class="title">Secondary outcomes</h5> <section id="CD007751-sec-0071"> <h6 class="title">Adverse events</h6> <p>ACEi may make little or no difference in reducing the number of adverse events compared to placebo at 4.8 years (median follow‐up) (<a href="./references#CD007751-fig-0011" title="">Analysis 1.8</a> (2 studies, 8873 participants): RR 1.33, 95% CI 1.26 to 1.41; I² = 0%; low certainty evidence). Types of adverse events are summarised in <a href="#CD007751-tbl-0004">Table 1</a> and <a href="#CD007751-tbl-0005">Table 2</a>. </p> <div class="table" id="CD007751-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Withdrawals and adverse events for angiotensin‐converting enzyme inhibitors versus placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]"><b>AIPRI 1996</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ACEi (benazepril)</b> </p> <p><b>(N = 300)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> <p><b>(N = 283)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Withdrawals due to adverse events</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>35</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertensive crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local or systemic allergic reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Withdrawals due to other events</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lack of cooperation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Violation of protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACEi ‐ angiotensin‐converting enzyme inhibitors</p> </div> </div> <div class="table" id="CD007751-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Number and types of adverse events for angiotensin‐converting enzyme inhibitors versus placebo</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]"><b>PEACE 2004</b> </a> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ACEi (trandolapril)</b> </p> <p><b>(N = 4158)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> <p><b>(N = 4132)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Number of events reported per adversity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1625 (39.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1136 (27.5%) (P &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119 (4.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161 (3.9%) (P = 0.04)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Angioedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (&lt; 1%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACEi ‐ angiotensin‐converting enzyme inhibitors</p> <p><a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a> and <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a> reported adverse events and withdrawals for those who were randomised at study level, but not for the relevant subgroups that were of interest for this review </p> </div> </div> </section> <section id="CD007751-sec-0072"> <h6 class="title">Kidney failure progression: change in eGFR</h6> <p>For patients whose baseline GFR was &gt; 45 mL/min/1.73m², <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a> reported no difference in the mean eGFR at 27 months between ACEi and placebo (ramipril: 0.19 mL/min/1.73 m² (standard error (SE) 0.07) in 99 participants; placebo: 0.34 mL/min/1.73 m² (SE 0.09) in 87 participants). </p> </section> <section id="CD007751-sec-0073"> <h6 class="title">Kidney failure progression: doubling of serum creatinine</h6> <p><a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a> reported a composite outcome of the combined total of participants 'experiencing doubling of SCr (mg/dL) or the need for dialysis' for 31 in 300 participants receiving an ACEi, compared with 57 in 283 participants receiving placebo, at three years. </p> </section> <section id="CD007751-sec-0074"> <h6 class="title">Proteinuria and albuminuria</h6> <p><a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a> observed a difference in urinary protein between ACEi and placebo at 36 months (benazepril: 29% decrease in urinary protein in 300 participants; placebo: 9% increase in urinary protein in 283 participants). The difference between the two treatments was not reported. </p> </section> <section id="CD007751-sec-0075"> <h6 class="title">Systolic blood pressure</h6> <p><a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a> reported the mean SBP at 6, 12, 24, and 36 months (benazepril: decrease by 4.5 to 8.0 mm Hg in 300 participants; placebo: increase of 1.0 to 3.7 mm Hg in 283 participants). </p> </section> <section id="CD007751-sec-0076"> <h6 class="title">Diastolic blood pressure</h6> <p><a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a> reported the mean DBP at 6, 12, 24, and 36 months (benazepril: decrease by 3.5 to 5.0 mm Hg in 300 participants; placebo: increase of 0.2 to 1.5 mm Hg in 283 participants). </p> <p><a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a> reported uncontrolled hypertension (benazepril: decrease by 28% to 18% in 300 participants; placebo: increase of 27% to 32% in 283 participants). </p> <p>No data were reported for the remaining primary or secondary outcomes.</p> </section> </section> </section> <section id="CD007751-sec-0077"> <h4 class="title">Angiotensin receptor blockers versus placebo</h4> <p><a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a> compared an ARB (losartan 50 mg/day) with a placebo in people with stage 3 CKD, over a 12‐month treatment period. </p> <p>See <a href="./full#CD007751-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD007751-sec-0078"> <h5 class="title">Primary outcomes</h5> <section id="CD007751-sec-0079"> <h6 class="title">Death (any cause)</h6> <p><a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a> reported that no patients died during the 12‐month study period (<a href="./references#CD007751-fig-0012" title="">Analysis 2.1</a> (226 participants; very low certainty evidence). </p> </section> </section> <section id="CD007751-sec-0080"> <h5 class="title">Secondary outcomes</h5> <section id="CD007751-sec-0081"> <h6 class="title">Adverse events</h6> <p><a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a> reported nine adverse events in 119 participants receiving ARB, and no adverse events in 119 participants receiving placebo (<a href="./references#CD007751-fig-0013" title="">Analysis 2.2</a> (1 study, 226 participants): RR 19.34, 95% CI 1.14 to 328.30; very low certainty evidence). The types of mild adverse events are summarised in <a href="#CD007751-tbl-0006">Table 3</a>. </p> <div class="table" id="CD007751-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events number and types angiotensin receptor blockers versus placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]"><b>Shen 2012</b> </a> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARB (losartan) (N = 199)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (N = 119)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of patients reporting an adverse event at 12 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of adverse events reported at 12 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Types and number of adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild dizziness</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ARB ‐ angiotensin receptor blockers</p> </div> </div> </section> <section id="CD007751-sec-0082"> <h6 class="title">Kidney failure progression: eGFR rate of decline</h6> <p><a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a> reported a difference in mean eGFR favouring ARB compared to placebo at 12 months (<a href="./references#CD007751-fig-0014" title="">Analysis 2.3</a> (1 study, 226 participants): MD 5.00 mL/min/1.73 m², 95% CI 3.03 to 6.97; very low certainty evidence). </p> </section> <section id="CD007751-sec-0083"> <h6 class="title">Kidney failure progression: doubling of serum creatinine</h6> <p><a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a> did not report a doubling of SCr but reported that a difference was found between the mean (± SD) SCr (mg/dL) favouring ARB compared to placebo at 12 months (losartan: 1.48 ± 0.27 to 1.51 ± 0.32 in 112 participants; placebo: 1.49 ± 0.28 to 1.69 ± 0.30 in 114 participants). </p> </section> <section id="CD007751-sec-0084"> <h6 class="title">Presence of proteinuria</h6> <p><a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a> reported a decrease in mean proteinuria with ARB (losartan 50 mg/day) compared to placebo at 12 months (<a href="./references#CD007751-fig-0015" title="">Analysis 2.4</a> (1 study, 226 participants): MD ‐0.65 g/24 hours, 95% CI ‐0.78 to ‐0.52; very low certainty evidence). </p> </section> <section id="CD007751-sec-0085"> <h6 class="title">Systolic blood pressure</h6> <p><a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a> reported no difference in the mean SBP between ARB and placebo at 12 months (<a href="./references#CD007751-fig-0016" title="">Analysis 2.5</a> (1 study, 226 participants): MD ‐0.80 mm Hg, 95% CI ‐3.89 to 2.29; very low certainty evidence). </p> </section> <section id="CD007751-sec-0086"> <h6 class="title">Diastolic blood pressure</h6> <p><a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a> reported no difference in the mean DBP between ARB and placebo at 12 months (<a href="./references#CD007751-fig-0017" title="">Analysis 2.6</a> (1 study, 226 participants): MD ‐1.10 mm Hg, 95% CI ‐3.29 to 1.09; very low certainty evidence). </p> <p>No data were reported for the remaining primary or secondary outcomes.</p> </section> </section> </section> <section id="CD007751-sec-0087"> <h4 class="title">Angiotensin‐converting enzyme inhibitors plus angiotensin receptor blockers versus placebo </h4> <p>No studies compared ACEi plus ARB with placebo.</p> </section> <section id="CD007751-sec-0088"> <h4 class="title">Angiotensin‐converting enzyme inhibitors versus angiotensin receptor blockers</h4> <p>Two studies compared an ACEi (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>: enalapril 20 mg; <a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>: perindopril 2 mg or trandolapril 1 mg), with an ARB (<a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a>: olmesartan 20 mg; <a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a>: losartan 25 mg or candesartan 4 mg) in people with CKD stage G1, G2, or G3, over a 12 to 48 week treatment period. </p> <p><a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a> investigated participants with CKD stage 2, and <a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a> stratified by baseline proteinuria level; those with mild (&lt; 1 g/day) and moderate (&gt; 1 g/day) proteinuria levels to classify approximately as CKD stage G1 and G2. <a href="./references#CD007751-bbs2-0002" title="EspinelE , JovenJ , GilI , SuneP , RenedoB , FortJ , et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes2013;6:306. [MEDLINE: 23915518]">Espinel 2013</a> conducted a two‐arm cross‐over study but did not report separate data for the first phase of the trial. </p> <p>See <a href="./full#CD007751-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD007751-sec-0089"> <h5 class="title">Primary outcomes</h5> <p>No data were reported on the primary outcomes of death (any cause), CVD events, or ESKD. </p> </section> <section id="CD007751-sec-0090"> <h5 class="title">Secondary outcomes</h5> <section id="CD007751-sec-0091"> <h6 class="title">Kidney failure progression: eGFR</h6> <p><a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a> reported "no effect" on creatinine clearance (mL/min/1.73 m²) when comparing ACEi to ARB over 48 weeks (52 participants total). </p> </section> <section id="CD007751-sec-0092"> <h6 class="title">Proteinuria</h6> <section id="CD007751-sec-0093"> <p><b>Subgroup analysis: low proteinuria group &lt; 1.0 g/day</b></p> <p><a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a> reported "no significant change" in mean proteinuria (g/day) when comparing ACEi to ARB at 12 and 48 weeks (26 participants total). </p> </section> <section id="CD007751-sec-0094"> <p><b>Subgroup analysis: high proteinuria group &gt; 1.0 g/day</b></p> <p>It is uncertain whether ACEi makes a difference to mean proteinuria compared to placebo at 12 weeks (<a href="./references#CD007751-fig-0018" title="">Analysis 3.1</a> (1 study, 26 participants): MD ‐0.50 g/24 hours, 95% CI ‐0.81 to ‐0.19; very low certainty evidence) or at 48 weeks (<a href="./references#CD007751-fig-0019" title="">Analysis 3.2</a> (1 study, 26 participants): MD ‐0.40 g/24 hours, 95% CI ‐0.60 to ‐0.20; very low certainty evidence). </p> </section> </section> <section id="CD007751-sec-0095"> <h6 class="title">Systolic blood pressure</h6> <section id="CD007751-sec-0096"> <p><b>Subgroup analysis systolic blood pressure: low proteinuria group &lt; 1.0 g/day</b></p> <p>It is uncertain whether ACEi makes a difference to SBP compared to placebo at 12 weeks (<a href="./references#CD007751-fig-0020" title="">Analysis 3.3</a>.1 (1 study, 26 participants): MD ‐2.00 mm Hg, 95% CI ‐4.31 to 0.31; very low certainty evidence). </p> <p><a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a> found no observed differences in change of SBP when comparing ACEi to ARB at 24 weeks (ACEi: 132 ± 4 mm Hg, N = 13; ARB: no values reported, N = 13) and 48 weeks (ACEi: 131 ± 4 mm Hg, N = 13; ARB: no values reported, N = 13). </p> </section> <section id="CD007751-sec-0097"> <p><b>Subgroup analysis systolic blood pressure: high proteinuria group &gt; 1.0 g/day</b></p> <p>It is uncertain whether ACEi makes a difference to SBP compared to placebo at 12 weeks (<a href="./references#CD007751-fig-0020" title="">Analysis 3.3</a>.2 (1 study, 26 participants): MD ‐3.00 mm Hg, 95% CI ‐6.08 to 0.08; very low certainty evidence). </p> <p><a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a> found no observed differences in change of SBP when comparing ACEi to ARB at 24 weeks (ACEi: 120 ± 3 mm Hg, N = 14; ARB: no values reported, N = 12) and 48 weeks (ACEi: 124 ± 3 mm Hg, N = 14; ARB: no values reported, N = 12). </p> </section> </section> <section id="CD007751-sec-0098"> <h6 class="title">Diastolic blood pressure</h6> <section id="CD007751-sec-0099"> <p><b>Subgroup analysis diastolic blood pressure: low proteinuria group &lt; 1.0 g/day</b></p> <p>It is uncertain whether ACEi makes a difference to DBP compared to placebo at 12 weeks (<a href="./references#CD007751-fig-0021" title="">Analysis 3.4</a>.1 (1 study, 26 participants): MD 5.00 mm Hg, 95% CI 2.57 to 7.43; very low certainty evidence). </p> <p><a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a> reported no difference in the change of DBP when comparing ACEi to ARB at 24 weeks (ACEi: 80 ± 3, N = 13; ARB: no values reported, N = 13) and 48 weeks (ACEi: 74 ± 4, N = 13; ARB: no values reported, N = 13). </p> </section> <section id="CD007751-sec-0100"> <p><b>Subgroup analysis diastolic blood pressure: high proteinuria group &gt; 1.0 g/day</b></p> <p>It is uncertain whether ACEi makes a difference to DBP compared to placebo at 12 weeks (<a href="./references#CD007751-fig-0021" title="">Analysis 3.4</a>.2 (1 study, 26 participants): MD ‐1.00 mm Hg, 95% CI ‐3.31 to 1.31; very low certainty evidence). </p> <p><a href="./references#CD007751-bbs2-0003" title="MatsudaH , HayashiK , HommaK , YoshiokaK , KandaT , TakamatsuI , et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertension Research - Clinical &amp; Experimental2003;26(11):875-80. [MEDLINE: 14714578]MatsudaH , HayashiK , SarutaT . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. Journal of Human Hypertension2003;17(4):271-6. [MEDLINE: 12692572]">Matsuda 2003</a> reported no difference in the change of DBP when comparing ACEi to ARB at 24 and 48 weeks (no values reported for either treatment group). </p> <p>No data were reported for the remaining secondary outcomes.</p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007751-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007751-sec-0101"></div> <section id="CD007751-sec-0102"> <h3 class="title" id="CD007751-sec-0102">Summary of main results</h3> <p>Six studies (9379 randomised participants) were included in this review, with sample sizes ranging from 30 to 8290 participants. Three studies were single‐centre, and three were multi‐centre, all taking place in hospital settings. Study participants were adults with CKD stages G1 to G3 from nine countries. Treatment periods ranged from 12 weeks to three years. Overall, studies were mostly judged to be at either unclear or high risk of bias across all domains. </p> <p>Low certainty evidence found ACEi (benazepril 10 mg or trandolapril 2 mg) compared to placebo made little or no difference to death (any cause), total cardiovascular events, cardiovascular‐related death, stroke, MI, and adverse events. Very low certainty evidence found ACEi (benazepril 10 mg or trandolapril 2 mg) compared to placebo had uncertain effects on congestive heart failure and TIA. </p> <p>Based on very low certainty evidence, ARB (losartan 50 mg) had uncertain effects on death (any cause), adverse events, eGFR rate of decline, presence of proteinuria, SBP, and DBP compared to placebo. </p> <p>Based on very low certainty evidence, ACEi (enalapril 20 mg, perindopril 2 mg or trandolapril 1 mg) (olmesartan 20 mg, losartan 25 mg or candesartan 4 mg) had uncertain effects on proteinuria, SBP and DBP, compared to ARB. </p> <p>There is very limited data to ascertain the benefits and harms of the use of ACEi or ARBs in adults with early (stages 1 to 3) non‐diabetic CKD. </p> </section> <section id="CD007751-sec-0103"> <h3 class="title" id="CD007751-sec-0103">Overall completeness and applicability of evidence</h3> <p>Despite the growing international emphasis on the early detection and management of CKD and the recognition that stage 1 to 3 CKD accounts for most people with evidence of kidney impairment, we found very few studies that reported the effectiveness of ACEi or ARB in this population. </p> <p>This review highlights the striking lack of studies in people with stage 1 to 3 CKD, which is the population group that accounts for most people identified as having CKD. Identification of CKD stages 1 and 2 requires evidence of kidney damage, such as confirmation of proteinuria, haematuria or structural abnormality. This requirement may make identifying people to participate in studies more challenging, and even more so for investigators looking into single, specific kidney diagnoses. </p> <p>The two major issues around the applicability of the evidence to clinical practice and patients were: </p> <p> <ul id="CD007751-list-0015"> <li> <p>definition of CKD, and</p> </li> <li> <p>the underlying pathologies that caused the kidney damage.</p> </li> </ul> </p> <p>The patient groups included in the studies varied considerably, particularly in terms of comorbidities and severity of proteinuria. This made it difficult to draw any overall conclusions. Each of the six included studies differed in their definitions of CKD in terms of eGFR cut‐off levels and measures of eGFR. These differences are particularly important when identifying a cohort of people with stage 3 CKD. Invariably, participants in each study differed in regard to their reported degrees of kidney impairment. </p> <p>Of the four studies that reported data for death (any cause) and CVD events, two defined their CKD groups based on single eGFR assays (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>; <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>) and therefore were prone to classification bias because of the chance of including people with AKI. Only two studies based the definition of CKD on an eGFR using standard equations (<a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a>; <a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]">Shen 2012</a>), which is the method most widely adopted in clinical practice, but likely to underestimate eGFR in those with true eGFR level of around 60 mL/min/1.73 m². </p> <p>The included patient population comprised mainly of hypertensive patients with varying renal pathologies, and 4% (<a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]">AIPRI 1996</a>) to 19% (<a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>) had DM at baseline. The high proportion of people with DM, and the inclusion of only people with existing CVD in <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a>, make it difficult to draw conclusions for the wider population with early CKD. <a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a> reported a reduction in death (any cause) consistent with other studies of ACEi in populations with CVD; however, the investigators did not report the statistically significant benefits in kidney outcomes that were observed in other studies conducted among diabetic study participants only. The proportions of patients with CVD and specifically reported kidney diagnoses varied from study to study. </p> <p>We identified a number of significant gaps in the evidence. No studies were identified that compared an ACEi combined with ARB versus placebo. Only some of the many preparations of ACEi and ARB drugs available were investigated in the studies, and none compared one preparation with another. Intervention features such as compliance, timing, dosing or intensity could not be elicited because of poor reporting in studies. Although most of the included studies reported on some measure of kidney function over time, death and ESKD, none reported QoL, healthcare costs, admissions to hospital, falls, fatigue, or dementia. </p> </section> <section id="CD007751-sec-0104"> <h3 class="title" id="CD007751-sec-0104">Quality of the evidence</h3> <p>Overall, the quality of the evidence was poor. Across all treatment comparisons, studies were downgraded primarily for serious limitations in the study design and execution, whereby studies were mostly judged to be at unclear or high risk of bias across all domains. Studies were also downgraded due to some uncertainty about the directness of the evidence or sparse data. The small number of studies, their relatively small size, and low event rates for some of the primary outcomes and single study data meant that the evidence was of very low certainty. Findings should therefore be viewed with caution. </p> <p>See <a href="./full#CD007751-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD007751-tbl-0002">summary of findings Table 2</a> and <a href="./full#CD007751-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD007751-sec-0105"> <h3 class="title" id="CD007751-sec-0105">Potential biases in the review process</h3> <p>This review was conducted as per the protocol following pre‐specified inclusion criteria and included comprehensive literature searches to find all relevant studies. Two authors screened all titles, abstracts and full papers to avoid selection bias. There was no arbitration required during the selection process, data extraction or quality assessment that needed a third author. </p> <p>We found very few studies reporting outcomes for the group of patients of interest in this review (stage 1 to 3 CKD). We excluded studies of single specific kidney diagnoses, and it is acknowledged that some of these may include patients with evidence of isolated proteinuria (stage 1 CKD). A large number of studies conducted in people with CKD were excluded because the authors did not report their findings in subgroups that were relevant to this study. In addition, studies of the use of ACEi and ARB drugs in hypertensive patients may also include people with stage 1 to 3 CKD. Before asking authors to consider re‐analysing data into specified subgroups, we considered it appropriate to establish what data were available in the published literature. </p> </section> <section id="CD007751-sec-0106"> <h3 class="title" id="CD007751-sec-0106">Agreements and disagreements with other studies or reviews</h3> <p>We did not find any other published reviews that matched our inclusion criteria. Two systematic reviews reported that ACEi was found to have little benefit over placebo or other antihypertensive drugs in reducing death (any cause) among patients with CKD or hypertension (P = 0.12) (<a href="./references#CD007751-bbs2-0105" title="JafarTH , SchmidCH , LandaM , GiatrasI , TotoR , RemuzziG , et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine2001;135(2):73-87. [MEDLINE: 11453706]">Jafar 2001</a>) or those with DM (<a href="./references#CD007751-bbs2-0127" title="StrippoliGF , BonifatiC , CraigM , NavaneethanSD , CraigJC . Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD006257. [DOI: 10.1002/14651858.CD006257]">Strippoli 2006</a>). <a href="./references#CD007751-bbs2-0105" title="JafarTH , SchmidCH , LandaM , GiatrasI , TotoR , RemuzziG , et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine2001;135(2):73-87. [MEDLINE: 11453706]">Jafar 2001</a> reported ACEi to be effective in reducing mean BP, protein excretion, and the risk of kidney progression, compared with placebo or other antihypertensive drugs. The 11 included studies in <a href="./references#CD007751-bbs2-0105" title="JafarTH , SchmidCH , LandaM , GiatrasI , TotoR , RemuzziG , et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine2001;135(2):73-87. [MEDLINE: 11453706]">Jafar 2001</a> used different measures of CKD. Baseline mean SCr was &gt; 155 µmol/L in all but two studies (where it was 124 µmol/L and 88 µmol/L). In general, these studies included participants with greater kidney impairment than we have included here. The findings reported by <a href="./references#CD007751-bbs2-0105" title="JafarTH , SchmidCH , LandaM , GiatrasI , TotoR , RemuzziG , et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine2001;135(2):73-87. [MEDLINE: 11453706]">Jafar 2001</a> were not stratified by CKD stage, and therefore, they could not be compared directly. </p> <p>In <a href="./references#CD007751-bbs2-0127" title="StrippoliGF , BonifatiC , CraigM , NavaneethanSD , CraigJC . Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD006257. [DOI: 10.1002/14651858.CD006257]">Strippoli 2006</a>, the meta‐analysis of 21 studies of 7295 patients with DM and CKD, reported no survival benefit was observed compared with placebo (RR 0.91, 95% CI 0.71 to 1.17), except when treated with maximum tolerable doses (RR 0.78, 95% CI 0.61 to 0.098). Similarly, in people with DM and CKD, ACEi produced a 31% risk reduction of ESKD compared with placebo (RR 0.60, 95% CI 0.39 to 0.93). These outcomes were found to be similar for ARB (RR 0.78, 95% CI 0.67 to 0.91). However, the findings were not reported separately by stage. </p> <p>One systematic review of patients with CKD (119 studies, 64,768 patients; <a href="./references#CD007751-bbs2-0128" title="XieX , LiuY , PerkovicV , LiX , NinomiyaT , HouW , et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. American Journal of Kidney Diseases2016;67(5):728-41. [MEDLINE: 26597926]">Xie 2016</a>) reported that the odds of kidney failure were reduced by 39% (OR 0.61, 95% credible interval 0.47 to 0.79) with ACEi and 30% (OR 0.70, 95% credible interval 0.52 to 0.89) with ARB compared to placebo. Odds reductions for major cardiovascular events were also reported for ACEi (OR 0.82, 95% credible interval 0.71 to 0.92) and ARB (OR 0.76, 95% credible interval 0.62 to 0.89) compared to placebo. However, these findings were not stratified by CKD stage. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007751-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram" data-id="CD007751-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007751-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD007751-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ACEi versus placebo, Outcome 1: Death (any cause)" data-id="CD007751-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: ACEi versus placebo, Outcome 1: Death (any cause)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ACEi versus placebo, Outcome 2: Cardiovascualar disease events: total (fatal and non‐fatal)" data-id="CD007751-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: ACEi versus placebo, Outcome 2: Cardiovascualar disease events: total (fatal and non‐fatal) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ACEi versus placebo, Outcome 3: Cardiovascular disease events: death" data-id="CD007751-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: ACEi versus placebo, Outcome 3: Cardiovascular disease events: death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ACEi versus placebo, Outcome 4: Cardiovascular disease events: stroke" data-id="CD007751-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: ACEi versus placebo, Outcome 4: Cardiovascular disease events: stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ACEi versus placebo, Outcome 5: Cardiovascular disease events: myocardial infarction" data-id="CD007751-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: ACEi versus placebo, Outcome 5: Cardiovascular disease events: myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ACEi versus placebo, Outcome 6: Cardiovascular disease events: congestive heart failure" data-id="CD007751-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: ACEi versus placebo, Outcome 6: Cardiovascular disease events: congestive heart failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ACEi versus placebo, Outcome 7: Cardiovascular disease events: transient ischaemic attack" data-id="CD007751-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: ACEi versus placebo, Outcome 7: Cardiovascular disease events: transient ischaemic attack </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ACEi versus placebo, Outcome 8: Adverse events (number reporting an adverse event)" data-id="CD007751-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: ACEi versus placebo, Outcome 8: Adverse events (number reporting an adverse event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ARB versus placebo, Outcome 1: Death (any cause) at 12 months" data-id="CD007751-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: ARB versus placebo, Outcome 1: Death (any cause) at 12 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ARB versus placebo, Outcome 2: Adverse events (number reporting an adverse event)" data-id="CD007751-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: ARB versus placebo, Outcome 2: Adverse events (number reporting an adverse event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ARB versus placebo, Outcome 3: Kidney failure progression at 12 months: eGFR" data-id="CD007751-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: ARB versus placebo, Outcome 3: Kidney failure progression at 12 months: eGFR </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ARB versus placebo, Outcome 4: Proteinuria at 12 months" data-id="CD007751-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: ARB versus placebo, Outcome 4: Proteinuria at 12 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ARB versus placebo, Outcome 5: Systolic blood pressure at 12 months" data-id="CD007751-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: ARB versus placebo, Outcome 5: Systolic blood pressure at 12 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ARB versus placebo, Outcome 6: Diastolic blood pressure at 12 months" data-id="CD007751-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: ARB versus placebo, Outcome 6: Diastolic blood pressure at 12 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ACEi versus ARB, Outcome 1: Proteinuria at 12 weeks" data-id="CD007751-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: ACEi versus ARB, Outcome 1: Proteinuria at 12 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ACEi versus ARB, Outcome 2: Proteinuria at 48 weeks" data-id="CD007751-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: ACEi versus ARB, Outcome 2: Proteinuria at 48 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ACEi versus ARB, Outcome 3: Systolic blood pressure at 12 weeks" data-id="CD007751-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: ACEi versus ARB, Outcome 3: Systolic blood pressure at 12 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007751-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/urn:x-wiley:14651858:media:CD007751:CD007751-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ACEi versus ARB, Outcome 4: Diastolic blood pressure at 12 weeks" data-id="CD007751-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_t/tCD007751-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: ACEi versus ARB, Outcome 4: Diastolic blood pressure at 12 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/media/CDSR/CD007751/image_n/nCD007751-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007751-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors versus placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ACEi versus placebo for early (stage 1 to 3) non‐diabetic CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with early (stage 1 to 3) non‐diabetic CKD </p> <p><b>Settings:</b> hospitals </p> <p><b>Intervention:</b> ACEi (benazepril 10 mg or trandolapril 2 mg) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ACEi</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Death (any cause)</b> </p> <p>Follow‐up: 3 to 4.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 2 and 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 2.00</b> </p> <p>(0.26 to 15.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>8873 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>76 per 1000</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>152 per 1000</b><br/>(20 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>CVD events: total (fatal and non‐fatal)</b> </p> <p>Follow‐up: 3 to 4.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 2 and 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.97</b> </p> <p>(0.90 to 1.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>8873 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>214 per 1000</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>207 per 1000</b><br/>(192 to 224) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Adverse events: number reporting an adverse event</b> </p> <p>Follow‐up: 3.6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 2 and 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.33</b> </p> <p>(1.26 to 1.41)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>8873 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>304 per 1000</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>405 per 1000</b><br/>(383 to 429) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kidney failure progression: doubling of SCr (mg/dL)</b> </p> <p>Follow‐up: not available</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ACEi:</b> angiotensin‐converting enzyme inhibitor; <b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>CVD:</b> cardiovascular disease; <b>RR:</b> risk ratio; <b>SCr</b>: serum creatinine </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded once (‐1) for serious limitations in the execution (due to risk of bias) </p> <p><sup>2</sup> Downgraded once (‐1) for indirectness, likely related to variability within subgroups due to historical definitions of CKD stages </p> <p><sup>3</sup> No meta‐analysed data from included studies. No GRADE rating for this outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors versus placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007751-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Angiotensin receptor blockers versus placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ARB versus placebo for early (stage 1 to 3) non‐diabetic CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with early (stage 1 to 3) non‐diabetic CKD </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> ARB (losartan 50 mg) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARB</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Death (any cause)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not estimable</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>226 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>No data<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CVD events</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No data<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Adverse events (number reporting an adverse event)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 19.34</b> </p> <p>(1.14 to 328.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>226 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/><b>very low<sup>2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Kidney failure progression: eGFR (mL/min/1.73m</b> ²<b>)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD Stage 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>226 (1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/><b>very low<sup>2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was <b>5 mL/min/1.73 m² higher in the ARB group</b> (3.03 higher to 6.97 higher) compared to the placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ARB:</b> angiotensin receptor blockers; <b>CI:</b> confidence interval; <b>CKD:</b> chronic kidney disease; <b>CVD:</b> cardiovascular disease; <b>eGFR:</b> estimated glomerular filtration rate; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No meta‐analysed data from included studies. No GRADE rating for this outcome </p> <p><sup>2</sup> Downgraded once (‐1) for serious limitations in the execution (due to risk of bias) </p> <p><sup>3</sup> Downgraded once (‐1) for sparse data: one study only </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Angiotensin receptor blockers versus placebo for early (stage 1 to 3) non‐diabetic chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007751-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors versus angiotensin receptor blockers for early (stage 1 to 3) non‐diabetic chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ACEi versus ARB for early (stage 1 to 3) non‐diabetic CKD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with early (stage 1 to 3) non‐diabetic CKD </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention A:</b> ACEi (enalapril 20 mg, perindopril 2 mg, trandolapril 1 mg) </p> <p><b>Intervention B:</b> ARB (olmesartan 20 mg, losartan 25 mg, candesartan 4 mg) </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARB</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ACEi</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death (any cause)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CVD events</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kidney failure progression</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ACEi:</b> angiotensin‐converting enzyme inhibitor; <b>ARB:</b> angiotensin II receptor blockers; <b>CI:</b> Confidence interval; <b>CVD:</b> cardiovascular disease. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> No meta‐analysed data from included studies. No GRADE rating for this outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors versus angiotensin receptor blockers for early (stage 1 to 3) non‐diabetic chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007751-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Withdrawals and adverse events for angiotensin‐converting enzyme inhibitors versus placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD007751-bbs2-0001" title="ApperlooAJ , RensmaPL . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [MEDLINE: 8684417]CurrenCG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):597. [MEDLINE: 8684418]HoganTJ , ElliottWJ , SetoAH , BakrisGL . Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics2002;20(1):37-47. [MEDLINE: 11817991]LocatelliF , CarbarnsIR , MaschioG , MannJF , PonticelliC , RitzE , et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney International - Supplement1997;52(63):S63-6. [MEDLINE: 9407424]LocatelliF , Del VecchioL , AndrulliS , MaraiP , TentoriF . The role of underlying nephropathy in the progression of renal disease. Kidney International - Supplement2000;57(75):S49-55. [MEDLINE: 10828762]MannJF , MaschioG , AlbertiD , AIPRI investigators. Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461248] MaschioG , AlbertiD , JaninG , LocatelliF , MannJ , MotoleseM , et al. The use of benazepril in the treatment of progressive renal disease [abstract]. In: 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:65. [CENTRAL: CN-00550723] MaschioG , AlbertiD , JaninG , LocatelliF , MannJF , MotoleseM , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine1996;334(15):939-45. [MEDLINE: 8596594]MaschioG , AlbertiD , LocatelliF , MannJF , MotoleseM , PonticelliC , et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. Journal of Cardiovascular Pharmacology1999;33 Suppl 1:S16-20. [MEDLINE: 10028949]MaschioG . Effect of benazepril in chronic renal insufficiency. New England Journal of Medicine1996;335(8):596-7. [CENTRAL: CN-00550722] PedersenEB . Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril [Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men ogsa oget mortalitet]. Ugeskrift for Laeger1996;158(41):5798-9. [MEDLINE: 8928272]vanHoutBA , SimeonGP , McDonnellJ , MannJF . Economic evaluation of benazepril in chronic renal insufficiency. Kidney International - Supplement1997;52(63):S159-62. [MEDLINE: 9407447]"><b>AIPRI 1996</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ACEi (benazepril)</b> </p> <p><b>(N = 300)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> <p><b>(N = 283)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Withdrawals due to adverse events</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>35</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertensive crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local or systemic allergic reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b><i>Withdrawals due to other events</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lack of cooperation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Violation of protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ACEi ‐ angiotensin‐converting enzyme inhibitors</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Withdrawals and adverse events for angiotensin‐converting enzyme inhibitors versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007751-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Number and types of adverse events for angiotensin‐converting enzyme inhibitors versus placebo</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]"><b>PEACE 2004</b> </a> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ACEi (trandolapril)</b> </p> <p><b>(N = 4158)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> <p><b>(N = 4132)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Number of events reported per adversity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1625 (39.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1136 (27.5%) (P &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119 (4.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161 (3.9%) (P = 0.04)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Angioedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (&lt; 1%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ACEi ‐ angiotensin‐converting enzyme inhibitors</p> <p><a href="./references#CD007751-bbs2-0004" title="BraunwaldE , DomanskiMJ , FowlerSE , GellerNL , GershBJ , HsiaJ , et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine2004;351(20):2058-68. [MEDLINE: 15531767]PfefferMA , DomanskiM , RosenbergY , VerterJ , GellerN , AlbertP , et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. American Journal of Cardiology1998;82(3A):25-30H. [MEDLINE: 9719019]SolomonSD , RiceMM , JablonskiA , JoseP , DomanskiM , SabatineM , et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation2006;114(1):26-31. [MEDLINE: 16801465]">PEACE 2004</a> and <a href="./references#CD007751-bbs2-0005" title="BrunettiM , PaganoE , TammuzzoL , BeniniR , RemuzziG , RuggenentiP . In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]. Journal of the American Society of Nephrology2000;11(Sept):57A. [CENTRAL: CN-00550419] HebertLA . Renoprotective therapy: how good can it get?Kidney International2000;57(1):343-4. [MEDLINE: 10620219]KramerBK , SchwedaF . Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study. Lancet1997;350(9079):736. [MEDLINE: 9291919]LocatelliF , Del VecchioL , AndrulliS . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2020-1. [MEDLINE: 9872277]MallamaciF , RuggenentiP , PernaA , LeonardisD , TripepiR , TripepiG , et al. ACE inhibition is renoprotective among obese patients with proteinuria. Journal of the American Society of Nephrology2011;22(6):1122-8. [MEDLINE: 21527660]MontagninoG . REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet1998;352(9145):2021-2. [MEDLINE: 9872278]PernaA , BeniniR , RemuzziG , RuggenentiP . In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):78A. [CENTRAL: CN-00447169] PorterAM . Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet1997;350(9079):736. [MEDLINE: 9291920]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]RemuzziG , TognoniG , RuggenentiP , PernaA , MaggiorreQ , PizzarelliF , et al. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Journal of Nephrology1991;4(3):193-202. [EMBASE: 22157068]RuggenentiP , GaspariF , PernaA , RemuzziG . Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]. BMJ1998;316(7130):504-9. [MEDLINE: 9501711]RuggenentiP , PaganoE , TammuzzoL , BeniniR , GarattiniL , RemuzziG . Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International2001;59(1):286-94. [MEDLINE: 11135082]RuggenentiP , PernaA , BeniniR , BertaniT , ZoccaliC , MaggioreQ , et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. Journal of the American Society of Nephrology1999;10(5):997-1006. [MEDLINE: 10232685]RuggenentiP , PernaA , BeniniR , RemuzziG . Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology1998;9(11):2096-101. [MEDLINE: 9808096]RuggenentiP , PernaA , GherardiG , BeniniR , RemuzziG . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases2000;35(6):1155-65. [MEDLINE: 10845831]RuggenentiP , PernaA , GherardiG , GariniG , ZoccaliC , SalvadoriM , et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354(9176):359-64. [MEDLINE: 10437863]RuggenentiP , PernaA , GherardiG , GaspariF , BeniniR , RemuzziG . Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet1998;352(9136):1252-6. [MEDLINE: 9788454]RuggenentiP , PernaA , GherardiG , GaspariF , RemuzziG , GISEN Group. Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):83A. [CENTRAL: CN-00447505] RuggenentiP , PernaA , MosconiL , MataloneM , GaspariF , GariniG , et al. The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):147A. [CENTRAL: CN-00447506] RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , GaspariF , et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International - Supplement1997;52(63):S54-7. [MEDLINE: 9407422]RuggenentiP , PernaA , MosconiL , MataloneM , PisoniR , RemuzziG . The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]. Nephrology1997;3(Suppl 1):S39. [CENTRAL: CN-00461630] RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney International1998;53(5):1209-16. [MEDLINE: 9573535]RuggenentiP , PernaA , RemuzziG , Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. Journal of the American Society of Nephrology2001;12(12):2832-7. [MEDLINE: 11729254]RuggenentiP , PernaA , RemuzziG , GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International2003;63(6):2254-61. [MEDLINE: 12753315]RuggenentiP , PernaA , ZoccaliC , GherardiG , BeniniR , TestaA , et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). Journal of the American Society of Nephrology2000;11(1):88-96. [MEDLINE: 10616844]SchadlichPK , BrechtJG , BrunettiM , PaganoE , RangoonwalaB , HuppertzE . Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics2001;19((5 Pt 1)):497-512. [MEDLINE: 11465309]">REIN 1991</a> reported adverse events and withdrawals for those who were randomised at study level, but not for the relevant subgroups that were of interest for this review </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Number and types of adverse events for angiotensin‐converting enzyme inhibitors versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007751-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events number and types angiotensin receptor blockers versus placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD007751-bbs2-0006" title="ShenPC , HeLQ , YangXJ , CaoHX . Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. Journal of Investigative Medicine2012;60(7):1041-7. [MEDLINE: 22914601]"><b>Shen 2012</b> </a> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARB (losartan) (N = 199)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (N = 119)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of patients reporting an adverse event at 12 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of adverse events reported at 12 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Types and number of adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild dizziness</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ARB ‐ angiotensin receptor blockers</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events number and types angiotensin receptor blockers versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/full#CD007751-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007751-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ACEi versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.26, 15.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 CKD stage G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 CKD stage G3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.55 [0.95, 59.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Cardiovascualar disease events: total (fatal and non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 CKD stage G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 CKD stage G3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.50, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Cardiovascular disease events: death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.26, 11.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 CKD stage G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 CKD stage G3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.49 [0.46, 157.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Cardiovascular disease events: stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.56, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 CKD stage G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.56, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 CKD stage G3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.11, 3.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Cardiovascular disease events: myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.84, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 CKD stage G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.84, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 CKD stage G3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.13, 6.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Cardiovascular disease events: congestive heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.59, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 CKD stage G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.59, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Cardiovascular disease events: transient ischaemic attack <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.06, 15.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 CKD stage G3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.06, 15.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse events (number reporting an adverse event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.26, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 CKD stage G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.26, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 CKD stage G3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.82, 1.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ACEi versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007751-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ARB versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Death (any cause) at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Adverse events (number reporting an adverse event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Kidney failure progression at 12 months: eGFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Proteinuria at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Systolic blood pressure at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Diastolic blood pressure at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ARB versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007751-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ACEi versus ARB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Proteinuria at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Proteinuria at 48 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Systolic blood pressure at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Low proteinuria group (&lt; 1.0 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 High proteinuria group (&gt; 1.0 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Diastolic blood pressure at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Low proteinuria group (&lt; 1.0 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 High proteinuria group (&gt; 1.0 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ACEi versus ARB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007751.pub3/references#CD007751-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007751.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007751-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007751-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007751-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007751-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD007751-note-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD007751-note-0016">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD007751-note-0012">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007751-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007751-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007751-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007751\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007751\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007751\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007751\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007751\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007751.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007751.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007751.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007751.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007751.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727944858"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007751.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727944862"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007751.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb8687f3f937f',t:'MTc0MDcyNzk0OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 